Spironolactone for Lymphoma

Phase 2

Waitlist Available

Led By Joerg Herrmann, MD

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline up to 6 months

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing two sets of medications to improve heart function in patients with heart issues after cancer treatment. One set includes standard heart medications, while the other adds drugs that lower cholesterol and remove extra fluid. The goal is to see which set helps the heart recover better and faster.

Eligible Conditions

Lymphoma
Breast Cancer
Blood Cancers
Sarcoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline up to 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline up to 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline up to 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Delta change in left ventricular ejection fraction [LVEF])

Secondary study objectives

Cardiac function recovery rates between group 1 and group 2

Time to recovery of cardiac function between group 1 and group 2

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Group II (pravastatin, spironolactone)Experimental Treatment4 Interventions

Patients receive standard clinical practice therapy as in Group I. Patients also receive pravastatin PO and spironolactone PO for 6 months.

Group II: Group I (carvedilol, lisinopril)Active Control2 Interventions

Patients receive carvedilol orally (PO) and lisinopril orally (PO), up-titrated to maximum tolerated doses as per standard clinical practice for 6 months.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Spironolactone

2005

Completed Phase 4

~14580

Carvedilol

2011

Completed Phase 4

~1410